Interestingly, saracatinib markedly impaired the phosphorylation of AKT in Sar-S HN6 and HN8 cells, whereas Sar-R HN12 and HN17 cells showed no or only modest reduction in phospho-AKT (Fig. 2a, b), suggesting that the AKT pathway more relies on Src activation in HNSCC cells carrying high levels of phospho-Src. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.